Back to Top Skip to main content
Alert Arrow ALERT!!

There are emergency procedures in place for parts of world due to weather.

Get the latest information on emergency prescription refills and PCM referral waivers. 

Presentations to the DoD P&T Committee

Pharmacoeconomic & Budget Impact Analyses (2010-2011)

Approximate annual expenditures, all points of service

  • Aug 2011 – Contraceptives [$163M]
  • Aug 2011 – Non-steroidal anti-inflammatory drugs [$150M]
  • Aug 2011 – New drugs: Butrans, Staxyn, Edarbi, Amturnide, Cycloset
  • May 2011 – Atypical antipsychotics [$218M]
  • May 2011 – Nasal allergy drugs [$95M]
  • May 2011 – New drugs: Kombiglyze XR, Bromday, Jalyn
  • Feb 2011 – Antilipidemic-2 agents (Fibrates, omega-3 fatty acid, bile acid sequestrants) [$140M]
  • Feb 2011 – Gastrointestinal-1 agents (aminosalicylates, pancreatic enzymes, misc) [$66M]
  • Feb 2011 – New drugs: Aricept 23mg, Tekamlo, Tribenzor, blood glucose test strips
  • Nov 2010 – Non-insulin antidiabetics [$336M]
  • Nov 2010 – New drugs: Dulera, Livalo, Silenor, Exalgo, Fibricor, Natazia
  • Aug 2010 – Renin-angiotensin antihypertensive agents [$300M]
  • Aug 2010 – Topical ophthalmic anti-allergy drugs (antihistamine, mast cell stabilizers, NSAIDs) [$18M]
  • May 2010 – Antilipidemic-I products (statins, niacin, ezetimibe) [$489M]
  • May 2010 – BPH alpha blockers [$80M]
  • May 2010 – New drugs: Sumavel, Onsolis
  • Feb 2010 – Basal insulins [$80M]
  • Feb 2010 – Antihemophilic agents [$38]
  • Feb 2010 – New drugs: Edluar, Embeda, Intuniv, Twynsta, Valturna

Patterns of Use/Effect of Formulary Interventions (2010-2011)

  • Aug 2011 – Closing the loop: effects of step therapy on beneficiary behavior in 7 major drug classes
  • Aug 2011 – Indications for use: montelukast (Singulair)
  • May 2011 – Utilization of atypical antipsychotics in the MHS
  • Feb 2011 – Utilization of antidiabetics in the MHS: HbA1cs at start of oral antidiabetic therapy
  • Nov 2010 – Utilization of antidiabetics in the MHS: new users and step therapy estimates
  • Nov 2010 – Closing the loop: early results of statin step therapy; utilization of PDE-5s
  • Aug 2010 – Renin-angiotensin antihypertensives in the MHS: diagnoses, prior and concomitant use
  • Aug 2010 – Closing the loop: following up on P&T decisions

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.